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ABSTRACT
Objective: The objective of this study was to evaluate the effect of the hydroalcoholic extract of Matricaria Chamomilla Linn. (CHAE) on lipids, 
lipoproteins, and antioxidants activity in isoproterenol (ISO)-induced myocardial infarcted rats.
Methods: ISO (85 mg/kg, s.c.)-induced myocardial infarction for 2 consecutive days at an interval of 24 h. Rats were pretreated with CHAE (100 and 
200 mg/kg, oral) for a period of 20 days and ISO was injected on 21 and 22 days at 24 h intervals and after 24 h, blood was collected through retro-
orbital plexus for the estimation of lipids, lipoproteins, and antioxidants assay.
Results: In the present study, ISO caused a significant increase in the concentration of total cholesterol, triglycerides, low-density lipoprotein 
cholesterol (LDL-C), very LDL-C, and lipid peroxidation whereas a significant decrease in the concentration of high-density lipoprotein-C. ISO 
administration also significantly decreased the activities of paraoxonase (PON) enzyme. Oral pre-treatment of CHAE at doses of 100 and 200 mg/kg 
body weight (bw) for 20 days challenged with a concurrent injection of ISO (85 mg/kg bw) on 21 and 22 days significantly attenuated these alterations 
and restored the levels of lipids and lipoproteins. In addition, CHAE significantly elevated the serum antioxidants enzyme PON and catalase (CAT).
Conclusion: The report revealed that pre-treatment with CHAE ameliorated lipid and lipoprotein and increased the antioxidant PON and CAT activity 
and decreased LPO level in ISO-treated male albino Wistar rats.
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INTRODUCTION
Myocardial infarction (MI) or heart attack is the leading cause of death 
for both men and women all over the world. MI occurs when blood supply 
is insufficient to the myocardium, death of myocardial muscle occurs, a 
condition known as ischemia. Prolonged ischemia of the myocardium 
leads to necrosis of myocardium cell, which is referred to as MI [1]. MI 
is the acute condition that occurs due to imbalance between coronary 
blood supply and demand [2]. The risk factors of cardiovascular diseases 
(CVDs) are high levels of total cholesterol (TC), triglycerides (TGs), low-
density lipoprotein cholesterol (LDL-C), and apolipoproteins A-I and low 
levels of high-density lipoprotein cholesterol (HDL-C). Cardiovascular 
diseases are directly or indirectly related to oxidative stress that causes 
molecular and cellular damage. Numerous medicinal plants have been 
evaluated for cardiovascular diseases in India and various parts of the 
world using cardiotoxic models [3].
Isoproterenol (ISO) is a β-adrenergic agonist that causes severe 
stress on the myocardium in heart muscle, leading to the necrosis of 
myocardium [4]. ISO causes an increase in the levels of serum and 
myocardial lipids and also increases the level of LDL-C in the blood 
that causes the blockage of arteries favoring CVD [5]. ISO stimulates 
lipid peroxidation (LPO) by inducing free radical production, which 
may be a causative factor of irreversible damage to the myocardial 
membranes [6]. Oxidative stress and oxygen-free radicals together lead 
to the generation of atherosclerotic lesions by the formation of oxidized 
LDL from LDL, which is the underlying cause of MI [7].
Matricaria chamomilla Linn. (CHAE) (synonym: Matricaria recutita) 
commonly known as chamomile or German chamomile belongs to the 
family Asteraceae [8,9]. Chamomile as a whole plant has been used 
traditionally in different forms for the treatment of multiple medical 
complaints such as common cold, bronchitis, gastrointestinal spasms, 
epilepsy, hypertension, neuralgia, toothache, dysmenorrhea, eczema, 
impetigo, indigestion, colic, and diarrhea [10-12]. Its flowers are also 
used as carminative and antipyretic, while its oil has been used in 
rheumatism, flatulence, and colic [13,14].
Phytochemical studies revealed the presence of alpha-bisabolol, 
cis-spiroethers sesquiterpenes (anthecotulid), cadinene, farnesene, 
furfural, spathulenol, and proazulene (Matricaria and matricin) as 
plant constituents. The presence of tannin in chamomile has also been 
detected <1% [15,16].
Pharmacological investigations showed that Matricaria chamomilla 
possesses anti-inflammatory [17], antispasmodic [18], antibacterial [19], 
digestive [20], antioxidant, and antidiabetic [21,22] activities.
Paraoxonase (PON) is synthesized in the liver and is bound to plasma 
HDL-C [23]. PON has treated as a component of the plasma antioxidant 
system. This enzyme prevents the oxidation of LDL-C and acts as 
a protective enzyme against atherogenesis. PON protects against 
atherosclerosis by reducing HDL-C peroxidation and protect plasma 
membranes from free radical injury [24]. Human serum PON has been 
shown to hydrolyze oxidized lipids and thus to decrease oxidative 
stress on serum lipoproteins [25]. Low activity of serum PON has 
been reported in diseases associated with hypercholesterolemia, 
atherosclerosis and increased prevalence of CVD [26].
In the present study, we assessed the ameliorative effect of CHAE on 
lipids, lipoproteins, catalase (CAT) activity, LPO, and PON in ISO-
administered myocardial infarcted rats.
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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MATERIALS AND METHODS
Collection and authentication of plant material
Matricaria chamomilla collected from local areas of Coimbatore 
district, Tamil Nadu, India. The collected flower parts of Matricaria 
chamomilla were authenticated by Dr. S Rajan, Field Botanist, Survey 
of Medicinal Plants and Collection Unit, Central Council for Research in 
Homoeopathy, Department of AYUSH, the Nilgiris, Tamil Nadu.
Extraction procedure
The dried plant material weighing 500 g used for extraction and soaked 
in 70% ethanol for 3 days, with occasional shaking. The soaked material 
was filtered through a muslin cloth and then through a Whatman 
qualitative Grade 1 filter paper. This procedure repeated 3 times and 
the combined filtrate was evaporated using a rotary evaporator to get 
the final aqueous-ethanolic extract of Matricaria chamomilla, yielding 
25% w/w [27].
Experimental animals
Healthy, adult Male Wistar albino rats (180–250 g) obtained from the 
central animal house facility, JSS College of Pharmacy, Udhagamandalam, 
Tamil Nadu. The animals were exposed in a well-ventilated room 
and were exposed to 12 h day and night cycle with a temperature 
between 22±3ºC. The animals were housed in large spacious, hygienic 
polypropylene cages during the course of the experimental period and 
fed with water ad libitum. All the experiments were performed after 
prior approval from the Institutional Animal Ethics Committee (JSSCP/
IAEC/M.PHARM/PH.CPLOGY/04/2013-14).
Induction of experimental MI
ISO was dissolved in normal saline and was subcutaneously injected 
into rats (85 mg/kg) at 24 h intervals for 2 days to induce experimental 
MI [28].
Experimental design
After a 1-week acclimation period, animals randomly divided into four 
groups (with six rats in each group) and treated as follows:
 Group I – Untreated control rats
 Group II – Pre-treatment of rats with ISO (85 mg/kg bw)
 Group III – Pre-treatment of rats with CHAE 100 mg/kg (oral) + ISO 
(85 mg/kg)
 Group IV – Pre-treatment of rats with CHAE 200 mg/kg (oral) + ISO 
(85 mg/kg)
CHAE was solubilized in distilled water. CHAE orally pre-treated to 
the rats for 20 days using an intragastric tube. ISO was solubilized in 
distilled water and administered to the rats by subcutaneous injection 
for the past 2 consecutive days. Animals were sacrificed by cervical 
decapitation. Blood was collected from heart puncture to separate 
serum and plasma. Tissue samples were separated and refrigerated at 
80 LC.
Biochemical measurements
The levels of serum TC and TGs were estimated using diagnostics kits 
from Erba Diagnostics (Mumbai) as described by Allian et al. [29]. 
HDL-C was estimated by utilizing the kit of Siemens Diagnostics Ltd., 
India, as described by Richmond [30]. Very LDL-C (VLDL-C) was 
calculated as VLDL-C = TG/5, whereas LDL-C was calculated as LDL-C = 
TC − (HDL-C + VL DL-C). Malondialdehyde (MDA) level was measured 
to estimate LPO by the method of Okhawa et al. [31]. PON activity was 
assayed by the method of Gan et al. [32].
Statistical analysis
Results analyzed statistically by performing one-way analysis of 
variance (ANOVA) followed by Tukey’s multiple comparison tests to 
assess differences between the groups. Data considered statistically 
significant at p<0.05. All the statistics were performed using GraphPad 
Prism, version 6.
RESULTS AND DISCUSSION
Effect of CHAE on lipids and lipoproteins
Fig. 2, and Tables 1 and 2 depict the effect of CHAE on serum lipids 
and lipoproteins (TC, TG, HDL-C, VLDL-C, and LDL-C) in normal 
and ISO-administered groups. Rats injected with ISO exhibited a 
significant (p<0.05) increase in the levels of serum TC, TG, LDL-C, and 
VLDL-C, except HDL-C which showed a significant (p<0.05) decrease 
Table 1: Effect of CHAE on cholesterol and triglycerides levels
Groups Cholesterol (mg/dl) Triglycerides (mg/dl)
Control 55.80±1.881 56.92±2.150
ISO 85 mg/kg 86.17±1.748 185.2±2.151
CHAE 100 mg/kg 65.62±1.957 139.2±3.195
CHAE 200 mg/kg 63.73±2.035 79.43±2.997
Values represent mean±SEM; n=6; #p<0.05 versus control. *p<0.05 versus ISO 
one-way ANOVA followed by Tukey’s multiple comparisons test
Fig. 1: Schematic representation of the experimental design of the study
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when compared to control rats. Pre-treatment with CHAE (100 and 
200 mg/kg bw) dose dependently decreased serum TC, TG, LDL-C, 
and VLDL-C levels significantly (p<0.05) and increased serum HDL-C 
levels significantly (p<0.05) when compared to ISO administered 
rats. Treatment of CHAE at 200 mg/kg bw in ISO-administered rats 
decreased the serum TC and LDL-C almost to near normal but not 
significantly (p<0.05) when compared to the control rats.
Lipids play a significant role in CVD. Hyperlipidemia and 
hypercholesterolemia are vital risk factors in the progress of MI. ISO-
administered MI is allied with elevated levels of circulatory lipids. In 
this study, ISO-administered rats showed significantly increased levels 
of TC, TGs in serum. The increased level of cholesterol in ISO-treated rats 
is due to an increased level of LDL-C taken from the blood circulation. 
Increased level of TGs is the prime risk factor of MI that is associated 
with cardiovascular disturbances. CHAE treatment ameliorated lipids 
and lipoproteins with a significant increase in HDL-C levels and a 
decrease in TC, TGs, LDL-C, and VLDL-C levels, which may be due to the 
hypocholesterolemia and hypolipidemic activities of CHAE [33].
Effect of CHAE on LPO
Fig. 3 represented the effect of CHAE on serum LPO marker MDA in 
control and ISO-administered rat groups. Rats administered with ISO 
showed significant (p<0.05) increase in the level of MDA in serum 
when compared to control rats. CHAE (100 and 200 mg/kg bw) dose 
decreased the level of MDA significantly (p<0.05) in serum as compared 
to ISO alone administered rats.
LPO plays a crucial role in the toxicity of heart and liver. LPO is an 
important pathogenic event in myocardial necrosis and accumulation 
of lipid hydroperoxides which reflects damage to the cardiac 
constituents [34]. The free radicals mediate membrane damage that 
may increase the level of lipid peroxides in ISO-administered MI. The 
present study revealed a significant increase in the level of MDA in the 
serum of ISO-administered rats. CHAE pre-treatment to ISO-treated 
rats minimized MDA content, clearly exhibiting that CHAE inhibited the 
LPO. The inhibition of LPO may be due to the antioxidative activities of 
CHAE [35].
Effect of CHAE on CAT
Fig. 4 shows the effect of CHAE on the activity of CAT in the serum 
of control and ISO-administered rats. Rats administered with ISO 
significantly (p<0.05) decreased the activities of CAT in the heart as 
compared to normal control group. However, treatment with CHAE (100 
and 200 mg/kg) significantly prevented the reduction in the activities 
of antioxidant CAT as compared to ISO alone administered rats.
CAT is a common enzyme, found in nearly all living organisms. It 
catalyzes hydrogen peroxide into water and oxygen and protects 
organisms from free radicals. CAT has one of the highest turnover 
numbers of all enzymes; one CAT molecule can convert millions of 
hydrogen peroxide molecules to water and oxygen each second. CHAE 
pre-treatment to ISO-treated rats increases the CAT level in serum, 
clearly exhibiting that CHAE enhanced the CAT activity.
Effect of CHAE on PON enzyme
Fig. 5 depicts the effect of CHAE on the activity of serum PON in control 
and experimental rats. Significant (p<0.05) decrease in the levels of 
Fig. 2: Effect of CHAE on lipids and lipoproteins in the serum 
of untreated and isoproterenol-administered rats. The bars 
represent mean±SEM; n=6; #p<0.05 versus control. *p<0.05 
versus ISO one-way ANOVA followed by Tukey’s multiple 
comparison tests
Fig. 3: Effect of CHAE on lipid peroxidation in the serum of 
untreated and isoproterenol-administered rats. The bars represent 
mean±SEM; n=6; #p<0.05 versus control. *p<0.05 versus ISO one-
way ANOVA followed by Tukey’s multiple comparison tests
Table 2: Effect of CHAE on LDL-C, VLDL-C, and HDL-C levels
Groups LDL-C (mg/dl) VLDL-C (mg/dl) HDL-C (mg/dl)
Control 10.17±0.587 11.386±0.43 34.24±2.038
ISO 85 mg/kg 36.16±0.03 370.05±0.43 12.96±1.361
CHAE 100 mg/kg 20.66±0.21 27.84±0.64 17.12±1.525
CHAE 200 mg/kg 20.78±0.656 15.886±0.6 27.06±2.091
Values represent mean±SEM; n=6; #p<0.05 versus control. *p<0.05 versus ISO one-way ANOVA followed by Tukey’s multiple comparison tests. LDL-C: Low-density 
lipoprotein cholesterol, VLDL-C: Very low-density lipoprotein cholesterol, HDL-C: High-density lipoprotein cholesterol
serum PON observed in rats administered with ISO as compared to 
control rats. CHAE (100 and 200 mg/kg bw) pre-treatment for a period 
of 20 days increased the activity of serum PON significantly (p<0.05) 
when compared to ISO alone administered rats.
CHAE treatment has been enhanced PON activity in ISO-treated 
groups. CHAE may directly elevate serum PON activity because both 
in vitro and in vivo introduction of antioxidant molecules were shown 
to preserve PON activity. CHAE may also favorable to PON by its anti-
hypercholesterolemia and antioxidant activities.
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CONCLUSION
The conclusion of our study is pre-treatment with CHAE exhibits 
ameliorative effects in ISO injected myocardial infraction rats by 
modulating lipids, lipoproteins, and antioxidants enzymes such 
as LPO, CAT, and PON at the dose of 100 mg/kg and 200 mg/kg bw. 
The possible mechanism of CHAE cardioprotection is due to its anti-
hypercholesterolemic, antihyperlipidemic, and antioxidant actions.
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